This review outlines the WHO's strategic plan for polio eradication and the challenges posed by continued use of the trivalent oral poliovirus vaccine.
Risks of trivalent OPV warrant ongoing clinical caution in eradication programs; leaves open optimal vaccine transition strategies for trials.
The review presents data on the current stature of the Global Polio Eradication Initiative of the WHO. The success of its implementation mainly depends on the solutions of the problems associated with continuing use of trivalent oral poliovirus vaccine (OPV): vaccine- associated paralytic poliomyelitis (VAPP) and vaccine-derived polioviruses (VDPV). The information about the polio immunization strategy proposed by WHO in «Polio Eradication and Endgame Strategic Plan 2013 - 2018» is presented.
No takes yet. Share an insight, caveat, or question.
Olga E. Ivanova (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: